Holland & Knight Health Dose: May 12, 2026

Looking Ahead

The U.S. House of Representatives and U.S. Senate are in session this week, with appropriations and the budget reconciliation process being top of mind and likely to dominate activities for the month of May. The House is expected to consider the fiscal year (FY) 2027 Military Construction-Veterans' Affairs (VA) appropriations bill on the House floor, as well as a number of potential amendments. It is also expected that healthcare committees of jurisdiction will have committee activities such as markups this week, including the House Committee on Energy and Commerce Subcommittee on Health.

Meanwhile, in the Senate, nominees will be considered on the floor and committees will begin initial work on the budget reconciliation package – though the Senate Committee on the Judiciary's initial executive business meeting about funding for agencies within the U.S. Department of Homeland Security (DHS) has been postponed. In a letter to his Democratic colleagues, Senate Minority Leader Chuck Schumer (D-N.Y.) laid out objections to the budget reconciliation package, writing that the package provides funding to the U.S. Immigration and Customs Enforcement (ICE) and U.S. Customs and Border Protection (CBP) without including what he sees as necessary safeguards or policies to reduce healthcare costs. Sen. Schumer shares that he plans to challenge provisions in the package through the "Byrd Rule" process – which determines whether provisions are germane to the rules of the reconciliation process and could begin as soon as this week – and will offer amendments to raise objections on the policies in the bill. President Donald Trump has requested a budget reconciliation package be on his desk by June 1, 2026, making this month a critical juncture for Congress to move swiftly and meet that goal.

Upcoming Events

Congress

• The Senate Committee on Appropriations Subcommittee on Commerce, Justice, Science, and Related Agencies will hold a hearing on May 12, 2026, titled "Hearings to Examine the President's Fiscal Year 2027 Budget Request for the Federal Bureau of Investigation; the Drug Enforcement Administration; the U.S. Marshals Service; and the Bureau of Alcohol, Tobacco, Firearms and Explosives."
• The Senate Judiciary Committee has postponed the executive business meeting that had been scheduled for May 12, 2026, to consider a portion of the budget reconciliation package. Other committees – such as the Senate Committee on Homeland Security and Governmental Affairs and the Senate Committee on the Budget – are expected to hold committee meetings next week on the budget reconciliation package.
• The Senate Appropriations Committee Subcommittee on Agriculture, Rural Development, Food and Drug Administration, and Related Agencies is scheduled to hold a hearing on May 13, 2026, titled "Hearings to Examine the President's Fiscal Year 2027 Budget Request for the U.S. Food and Drug Administration."
• The Senate Homeland Security and Governmental Affairs Committee will hold a hearing on May 13, 2026, titled "Hearings to Examine Whistleblower Testimony on COVID."
• The Senate Special Committee on Aging will hold a hearing on May 13, 2026, titled "Caught in the Middle: Supporting Families in the Sandwich Generation."
• The House Committee on Energy and Commerce Subcommittee on Health will hold a markup on May 13, 2026, on a variety of public health reauthorization bills and policies to improve the U.S. Food and Drug Administration (FDA) and the Medicare program, including:
  • R. 4348, To reauthorize the Kay Hagan Tick Act, and for other purposes (Reps. Chris Smith (R-N.J.) and Lloyd Doggett (D-Texas)) 
  • R. 4541, EARLY Act Reauthorization of 2025 (Reps. Debbie Wasserman Schultz (D-Fla.) and Mariannette Miller-Meeks (R-Iowa)) 
  • R. 3747, Accelerating Access to Dementia and Alzheimer's Provider Training (AADAPT) Act (Reps. Troy Balderson (R-Ohio) and Nanette Barragán (D-Calif.)) 
  • R. 8209, School-Based Health Centers Reauthorization Act of 2026 (Reps. Paul Tonko (D-N.Y.) and Balderson) 
  • R. 5160, Stem Cell Therapeutic and Research Reauthorization Act of 2025 (Reps. Smith and Doris Matsui (D-Calif.)) 
  • R. 8205, Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026 (Reps. Mike Quigley (D-Ill.) and Ken Calvert (R-Calif.)) 
  • R. 2715, Destruction of Hazardous Imports Act (Reps. Clay Higgins (R-La.) and Troy Carter (D-La.)) 
  • R. 2821, FDA Modernization Act 3.0 (Reps. Buddy Carter (R-Ga.) and Barragán)
  • R. 5347, Health Care Efficiency Through Flexibility Act (Rep. Vern Buchanan (R-Fla.)) 
  • R. 1703, Choices for Increased Mobility Act of 2025 (Rep. John Joyce (R-Pa.)) 

Federal Agencies

• The Centers for Medicare & Medicaid Services (CMS) Medicare Advisory Panel on Clinical Diagnostic Laboratory Tests will hold a public meeting on June 10, 2026, to receive public comments and recommendations on the basis for establishing payment amounts for new or revised codes considered for Medicare payment under the Clinical Laboratory Fee Schedule for calendar year 2027. The panel advises the U.S. Department of Health and Human Services (HHS) secretary and CMS administrator on issues related to clinical diagnostic laboratory tests. Additional meetings will be held July 14-15, 2026, and September 15-16, 2026.
• The HHS and CMS Healthcare Advisory Committee will hold its first meeting on May 18, 2026, from 2 to 4:30 p.m. The committee is intended to advise the HHS secretary and CMS administrator on programs and policies to improve the U.S. healthcare system. The agenda for the meeting is expected to be posted one week in advance of the meeting.

Administrative Updates

Holland & Knight's Health AI Navigator

Holland & Knight's Health Artificial Intelligence (AI) Navigator is a centralized, interactive resource designed to help healthcare stakeholders track and interpret the rapidly evolving legal and regulatory landscape for AI in healthcare. The Navigator provides regularly updated summaries of federal and state legislative, regulatory and executive activity affecting the development, oversight and utilization of AI across the healthcare sector, including activity at Congress, HHS and the White House. In addition to a federal tracker, the Navigator features an interactive state‑by‑state map highlighting enacted and proposed laws impacting AI in healthcare, alongside curated analysis from Holland & Knight professionals. The tool is intended to support providers, payers, developers and investors seeking to understand emerging requirements, policy trends and compliance considerations as AI adoption continues to expand across healthcare.

Executive Order Updates

The Trump Administration has continued to release wide-ranging executive orders (EOs). For the latest updates, see our "Trump's Second-Term Executive Orders (2025-2026)" tracking chart.

• Promoting Efficiency, Accountability, and Performance in Federal Contracting (EO 14398): Issued April 30, 2026, the EO imposes new requirements for fixed-price contracts with performance-based incentives and requires them to serve as the default and preferred method of federal procurement. Moving forward, the EO directs the use of any non-fixed price contract – such as cost-reimbursement, time-and-material, labor-hour or any other non-fixed price contract – to be justified by contracting officers in writing to the head of the respective federal agency. The EO also directs written justifications be provided by contracting officers to agency heads for non-fixed price contracts valued over certain amounts that vary by federal agency, specifically the U.S. Department of War, NASA, DHS or any other agency. Within 90 days, the agency heads are directed to review and, to the maximum extent possible, modify, restructure or renegotiate the 10 largest non-fixed price contracts by dollar value to use fixed prices and performance-based incentives for contract deliverables. The restrictions shall not apply to contracts that involve research and development, or pre-production development for major systems acquisitions. The EO also directs within 45 days the Office of Management and Budget to issue guidance to implement policies from the EO. For further analysis, see Holland & Knight's alert, "Fixed Price, First Choice: New EO Pushes Agencies Further Away from Non-Fixed-Price Contracts," May 1, 2026.

Personnel Updates

• Katherine Szarama is now the acting director of the U.S. Food and Drug Administration's (FDA) Center for Biologics Evaluation and Research (CBER). She was previously a program manager at the Advanced Research Projects Agency for Health (ARPA-H). FDA Commissioner Dr. Martin Makary previously indicated that a new CBER director will be announced in the coming weeks at a press conference related to the FDA's clinical trial announcements.
• Nicole Saphier has been nominated to be U.S. Surgeon General. Saphier has been nominated in place of Casey Means whose nomination for the same position was unable to garner the requisite number of votes to advance in the Senate.
• FDA Commissioner Makary has resigned from his role at the FDA. Deputy Commissioner for Human Food Kyle Diamantas will serve as acting commissioner.

Congressional Updates

Overview of the Budget Reconciliation Package

The House adopted on a party-line vote on April 29, 2026, a budget resolution to enable Senate and House Republicans to continue the process of drafting and advancing the second budget reconciliation package of this Congress. The budget reconciliation process allows for Congress to consider and pass on an expedited basis – and with a simple majority – legislation that impacts or has policies related to the federal budget. The budget resolution was adopted by the Senate on April 23, 2026, and directs the House Committee on Homeland Security, House Committee on the Judiciary, Senate Homeland Security and Governmental Affairs Committee and Senate Judiciary Committee to submit recommendations for legislation totaling up to $70 billion in funding from FY 2026-2035. The recommendations are intended to be provisions that will ultimately constitute the text for the reconciliation package and are due to the committees by May 15, 2026, making this week crunch time for committee activity in the House and Senate. Though healthcare provisions are currently not included in the legislation – nor did healthcare committees of jurisdiction receive instructions in the reconciliation package – there is always a possibility that some within the Republican House who are pushing for a more wide-ranging package could seek to weave in provisions related to healthcare, if not in the reconciliation package then possibly as part of a larger effort encompassing a package of "clean up" items considered by various committees as the summer recess nears.

Energy and Commerce Democrat Leaders Write to Kennedy on Vaccine Data

Democrat leaders on the House Energy and Commerce Committee – including Ranking Member Frank Pallone (D-N.J.), Subcommittee on Health Ranking Member Diana DeGette (D-Colo.) and Subcommittee on Oversight and Investigations Ranking Member Yvette Clarke (D-N.Y.) – sent a letter to HHS Secretary Robert F. Kennedy Jr. on May 6, 2026, regarding a recent decision by the National Institutes of Health (NIH) Director and Acting Director of the Centers for Disease Control and Prevention (CDC) Dr. Jay Bhattacharya to hold back publication of scientific study on the effectiveness of the COVID-19 vaccine. The study was initially slated to be published in the CDC's Morbidity and Mortality Weekly Report but was removed from the publication. The letter requests answers to a number of questions by May 20, 2026, including whether 1) other studies have been held back since the beginning of the Trump Administration, 2) other CDC weekly reports have been subject to heightened internal scrutiny and 3) the CDC has had discussions with staff in the White House regarding the decision to pull the study from the published report. The letter lays out what a Democrat-led committee could look like, should the results of the November 2026 election fall in the favor of the Democrats.

Chairman Comer Shares Concerns with CPT Code System Driving Up Healthcare Costs

House Committee on Oversight and Governmental Affairs Chair James Comer (R-Ky.) sent a letter to a leading association representing physicians on April 30, 2026, regarding the role of the Current Procedural Terminology (CPT) coding system in driving up healthcare costs. The letter requests a staff-level briefing from CMS on oversight of the CPT system, writing that the system plays a central role in determining how billions of taxpayer dollars are utilized each year for care through Medicare and Medicaid. The letter also cites that improper billing within Medicare Advantage (MA) remains a top concern.

Regulatory Updates

FDA Seeks Input on AI‑Enabled Early‑Phase Clinical Trials Pilot Program

The FDA has issued a request for information (RFI) on a proposed pilot program to evaluate how AI‑enabled technologies could improve the efficiency, speed and quality of decision-making in early‑phase clinical trials. The initiative would allow FDA to monitor high‑level safety and efficacy signals in near-real time without collecting patient‑level data. FDA officials said the approach could reduce drug development timelines by months or longer and improve visibility into trials while they are underway. Commissioner Makary had framed the proposal as part of a broader effort to strengthen U.S. competitiveness in clinical research as sponsors increasingly initiate trials overseas, while FDA Chief AI Officer Jeremy Walsh said the program could be particularly beneficial for small and emerging biotech companies. The effort aligns with the White House budget signal that the FDA intends to provide new mechanisms to expedite early‑stage drug development.

Commerce Department Misses Deadline to Identify "Onerous" State AI Laws

The U.S. Department of Commerce has not yet published its expected report identifying state AI laws deemed "onerous," despite a March 11, 2026, statutory deadline established by EO 14365, "Ensuring a National Policy Framework for Artificial Intelligence," signed on December 11, 2025, as explained in a previous Holland & Knight alert. The report is intended to inform federal policymakers about state‑level AI requirements that could impede innovation or create compliance challenges. As of this week, the Commerce Department has not released a list or an updated timeline for publication. Within the healthcare sector, technology companies, physician groups, hospital systems and life sciences companies are currently navigating a growing patchwork of state AI laws governing healthcare delivery, including clinical decision support tools and coverage determinations. As constituent interest and attention increases on AI risk mitigation, this report may guide how lawmakers convene around next steps on legislating on this issue.

CMS Extends GENEROUS Deadline

CMS announced on April 29, 2026, that it would extend the deadline for drug manufacturers to apply for the GENErating cost Reductions fOr U.S. Medicaid (GENEROUS) model, intended to lower Medicaid prescription drug payment. Drug manufacturers now have until June 11, 2026, to apply, which is an extension from April 30, 2026. CMS is also extending the deadline for drug manufacturers to enter into participating agreements from June 30, 2026, to July 17, 2026.

FDA Releases Infant Formula Testing Update

The FDA released results from infant formula testing on April 29, 2026, completed as part of Operation Stork Speed, which was launched in March 2025 to improve access to safe, reliable supplies of infant formula nationwide following instances of contamination or recalls. As part of the testing, the FDA evaluated 312 infant formula samples across 16 brands for presence of lead, mercury, cadmium, arsenic, 30 Per- and polyfluoroalkyl substances (PFAS) compounds, 318 pesticides, 21 phthalates and certain other substances. The testing found that 99 percent of formula samples tested had no pesticides, and no detections for 25 of 30 compounds tested were found. It is unclear whether the FDA plans to address the limited number of products that indicated the presence of substances of concern.

HHS Initiates Action Plan to Reduce Prescription of Antidepressants Among Youths

The HHS announced new efforts on May 4, 2026, aimed at reducing the prescribing of psychiatric medicines to youth patients. In a dear colleague letter, the HHS encourages clinicians and providers to use informed consent and shared decision making in the prescribing of psychiatric medicines, including a discussion on purpose for use of the medication, sharing of possible adverse events, benefits and potential alternatives. Non-pharmacological interventions are emphasized as an alternative. To further the action plan, the Substance Abuse and Mental Health Services Administration (SAMHSA) will issue a report on prescribing trends and will hold webinars to prescribers and other health professionals on the side effects of certain medications and approaches to "deprescribing." SAMHSA and the Health Resources and Services Administration (HRSA) will host a separate webinar for federally qualified health centers on holistic care. In July 2026, the HHS will convene a Technical Expert Panel to gather input to inform the development of formal HHS clinical guidance on the appropriate use of psychiatric medications, tapering and discontinuation.

RFI and Comment on Impact of Patient-Focused Drug Development Meetings

The FDA issued an RFI and comment on April 30, 2026, to collect examples about how patient-focused drug development meetings may have impacted stakeholder drug development efforts. The deadline for comments is June 30, 2026. As directed by the Federal Food, Drug, and Cosmetic Act (FD&C), the FDA developed and implemented strategies to provide patients, caregivers and other stakeholders opportunities to offer structured feedback to inform how a disease or condition and treatment of the disease or condition are meaningful to patients. Both FDA-led and external stakeholder-led meetings will be assessed regarding the impact on the drug development process. As part of the RFI, the FDA poses questions regarding how meetings informed patient communities and stakeholder engagement, whether gaps in information or otherwise were filled or uncovered as a result of the meetings, and impacts on clinical practice.

FDA Proposes to Leave Three Ingredients Used in GLP-1 Products from 503B List

the FDA published a notice in the Federal Register on April 30, 2026, proposing to exclude semaglutide, tirzepatide and liraglutide from the Section 503B bulk drug substances list. This means that the FDA does not believe there is a clinical need for outsourcing facilities to compound semaglutide, tirzepatide and liraglutide. The FDA stated specific reasons for not including them:

• The FDA could not find a clinical need for an outsourcing facility to compound semaglutide to meet "related health conditions as determined appropriate by medical provider[s]." For oral sublingual and buccal products, the FDA could not identify a basis to conclude that oral and injectable routes of administration cause products to be medically unsuitable for certain patients. For injectable products, the FDA could not identify concentrations that made injectable products medically unsuitable for patients, nor was there good reason for oral compounded products to be made in capsule form.
• The FDA did not identify supporting data or information related to risks for adverse cardiovascular events and any attribute of tirzepatide that would make it medically unsuitable, among other reasons.
• The FDA tentatively found no basis to conclude the strength of FDA-approved liraglutide products make them medically unsuitable for patients.

Section 503B of the FD&C outlines conditions that must be met for drug products compounded by an outsourcing facility to be exempt from approval requirements under a new drug application or abbreviated new drug application. The FDA is completing reviews of other bulk drug substances nominated for inclusion on the 503B bulk drug substances list and will post additional Federal Register notices on a rolling basis. Public comments may be submitted prior to the FDA finalizing the proposal. The deadline is June 30, 2026.

FDA Issues Notice to Collect Tobacco Use Information to Inform Annual Survey

The FDA issued a notice on May 4, 2026, announcing an opportunity to provide public comment on issues related to youth tobacco use and access to tobacco products in the U.S. Public comments are due by July 6, 2026, and will inform the FDA's development of the annual National Youth Tobacco Survey. The survey supports the FDA's evaluation and work on policies related to reducing tobacco use among youth, such as through public education campaigns and regulatory activities.

PDUFA Program Fee Invoices to be Issued August 2026

In a public letter to prescription drug manufacturers, the FDA announced that program fee invoices for Prescription Drug User Fee Act (PDUFA) fee-eligible products will be issued August 2026. Under PDUFA VII, passed by Congress in 2022, the FDA is authorized to assess and collect fees for both human drug applications and prescription drug program fees. A program fee is assessed each year for certain prescription drug products identified in a human drug application approved as of October 1 of each FY. The letter asks recipients to confirm or correct company contact information and program fee-eligible products no later than June 1, 2026. The letter recommends companies review current listings of drug products in the Orange Book and notify the agency of any changes to product marketing status. Efforts on invoices from this calendar year will occur alongside ongoing efforts by the FDA and drug company stakeholders to finalize work toward reauthorization of PDUFA, which remains in progress. The FDA and drug company stakeholders are in the process of drafting and finalizing a commitments letter to outline policies that were agreed upon from the past several months of meetings and negotiations.

FDA Expands Internal AI Capabilities and Consolidates Data Systems

The FDA announced the expansion of its internal AI capabilities alongside the consolidation of more than 40 FDA data sources and systems into a single agency‑wide platform known as Harmonized AI and Lifecycle Operations for Data (HALO). The agency also launched Elsa 4.0, a major upgrade to its internal AI assistant developed based on direct feedback from FDA staff. Elsa 4.0 introduces capabilities beyond basic question‑and‑answer functions, including the ability to build personalized AI agents, analyze datasets, generate data visualizations, enable voice‑to‑text dictation and convert scanned documents and images into searchable text. FDA said the upgrades are intended to help employees across the agency work more efficiently and improve access to data for scientific review, compliance and oversight activities.

FDA Launches One‑Day Inspection Pilot for Low‑Risk Facilities

The FDA launched a new pilot program allowing agency investigators to conduct one‑day screening inspections at manufacturing facilities identified by AI as lower risk. The initiative applies to both domestic and international facilities and is intended to streamline FDA's inspection process while reallocating resources toward higher‑risk sites. FDA Commissioner Makary said the pilot is part of a broader effort to modernize oversight activities and make FDA inspections more efficient without compromising safety or quality standards.

FDA Authorizes Flavored Vapes for Adult Use

The FDA has authorized the marketing of four flavored electronic nicotine delivery system products for adults aged 21 and older, marking the first time the agency has permitted non‑tobacco, non‑menthol vape flavors. The products were authorized through the premarket tobacco product application pathway after FDA determined that the combination of device‑based age‑verification technology and marketing restrictions is expected to limit youth access. FDA emphasized that the products are authorized for sale but are not approved or endorsed, and said the agency will continue to closely monitor marketing practices and public health impacts.

New RFI on Repurposing Drugs for Unmet Medical Needs

The FDA released a new RFI on May 11, 2026, and established a public docket regarding drug repurposing to address unmet medical needs. As part of the RFI, the FDA requests information on potential priority disease areas and potential candidates for drug repurposing, with a focus on FDA-approved drugs for which there is no commercial interest in adding a new use for through a supplemental new drug application. Comments are due July 12, 2026.

Commerce Lays Out Procedures for Company-Specific Onshoring Agreements

The Commerce Department's Bureau of Industry and Security issued a notice in the Federal Register on May 11, 2026, to outline procedures by which companies may apply for company-specific onshoring agreements and obtain adjustments on duty rates under Section 232 of the Trade Expansion Act for pharmaceuticals and pharmaceutical ingredients. Companies are requested to submit applications within 30 days. As part of President Trump's April 2026 announcement and actions on tariffs for pharmaceutical products and ingredients, it was stated that companies that pursue agreements with the Trump Administration and Commerce Department to domestically manufacture pharmaceuticals and pharmaceutical ingredients (so-called onshoring agreements) are eligible for a reduced tariff rate of zero percent through 2029. The notice includes information required for applicants to submit, including what products a company manufactures and where, total investments, an onshoring commitment, percentage of U.S. and global sales produced in the U.S., and the contours of the financial investments an applicant envisions making to onshore any of its products or ingredients.

Proposed Rule on Fertility Benefits Related by Departments of Labor, HHS and Treasury

The Departments of Labor, HHS and Treasury issued a proposed rule to amend the Employee Retirement Income Security Act (ERISA) and allow employers to offer certain fertility benefits to employees. The proposed rule follows EO 14216, titled "Expanding Access to In Vitro Fertilization" issued on February 18, 2025. The EO seeks to ensure access to fertility treatment and expand treatment options available to families. The proposed rule would recognize fertility benefits as a new, additional category of excepted benefits when certain conditions are met - such as when fertility benefits are provided under a separate policy, certificate or contract of insurance or are otherwise not an integral part of an employer sponsored health plan – and proposes a maximum lifetime benefit cap of $120,000. Public comments on the proposed rule are due in 60 days from the publishing of the rule in the Federal Register.

FDA Issues RFIs on Uses and Safety Data for Two Chemicals: ADA and BHT

The FDA issued two RFIs on May 12, 2026, including for azodicarbonamide (ADA) and butylated hydroxytoluene (BHT) in human food and as a food contact substance. Comments and feedback from the public will inform the FDA’s post-market assessment of the safety of ADA and BHT in food to determine whether ADA and BHT remain safe under current conditions for use, based on and considering the most recent science. ADA is used as a whitening agent in cereal flour and as a dough conditioner in breadmaking, with applications in manufacturing foot contact materials. BHT is used as an antioxidant in food to prevent spoilage of fats and oils, as well as an antioxidant in food contact materials. In its requests for information on ADA and BHT, the FDA requests answers to questions such as general food categories the substances are used in, typical and maximum use levels, market share of foods substances are used in, biomonitoring data, documentation of generally recognized as safe (GRAS) conclusions and other areas. Public comments are due in 60 days from the publishing of the RFIs in the Federal Register.

Legal Updates

Supreme Court Appears Inclined Toward Limited Ruling in Skinny Label Case

Oral arguments were held before the U.S. Supreme Court on April 29, 2026, in a case involving "skinny labels," where generic drug manufacturers may seek approval from the FDA on uses for a medication that are not patented by the brand drug manufacturer. The justices appear inclined toward a more limited ruling and could send the case back to a lower court for further consideration, with Justice Neil Gorsuch indicating the court is more likely to reverse and remand the case, given public information related to the pleadings indicate there may have been patent infringement by a generic company. The comments from Justice Gorsuch and others during oral arguments indicate the Court will work to balance the need for competition within the generic drug marketplace and the need to avoid patent infringement issues. A decision in the case is expected by July 2026.

Supreme Court Pauses Mifepristone Stay, Reinstates Access via Telehealth

The Supreme Court temporarily paused a lower court's stay on access to the abortion medication mifepristone on May 4, 2026, reinstating access to the medication via telehealth. The U.S. Court of Appeals for the Fifth Circuit on May 1, 2026, directed the FDA to temporarily re-impose in-person dispensing requirements for mifepristone. The case was initially brought by a group of plaintiffs in Louisiana who sought to prohibit the distribution of abortion medication by mail and re-impose dispensing requirements that the FDA removed in 2023 following a revision to the risk evaluation and mitigation strategy (REMS). There are continued concerns from some particularly in the pharmaceutical industry that the court, should it choose to rule in favor of the plaintiffs, could upend the historical approval process for prescription drug products by shifting considerations from the FDA to the judicial system. The justices extended a stay on the order to reinstate access to abortion medicine via telehealth until May 14, 2026, as the initial stay was set to expire May 11, 2026, indicating the court may move quickly to take action in the coming days.

Information contained in this alert is for the general education and knowledge of our readers. It is not designed to be, and should not be used as, the sole source of information when analyzing and resolving a legal problem, and it should not be substituted for legal advice, which relies on a specific factual analysis. Moreover, the laws of each jurisdiction are different and are constantly changing. This information is not intended to create, and receipt of it does not constitute, an attorney-client relationship. If you have specific questions regarding a particular fact situation, we urge you to consult the authors of this publication, your Holland & Knight representative or other competent legal counsel.